Imugene Limited

    Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein

    Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology firm. The company is developing a range of new and novel immunotherapies that basically activates...
    Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

    Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

    Biotechnology company, Imugene Limited (ASX: IMU) is an emerging leader in cancer immuno-oncology which has made significant progress in the recent past. Today, the...
    IMU

    Imugene released research study of PD-1 mimotope cancer vaccine

    Imugene Limited (ASX: IMU) is a biotechnology company, having operations in America and Europe is working specifically in the clinical stage of immuno-oncology. Immuno-oncology...
    IMU

    Imugene Presented New Data On the KEY-Vaxx & B-Vaxx Cancer Vaccine

    Imugene Limited (ASX: IMU) is an immuno-oncology company, which is into the clinical stage. The company is engaged in the operations of developing a...

    Imugene provides Guidance for KEY-Vaxx Cancer Immunotherapy

    Imugene Limited (ASX: IMU) is an ASX listed biotechnology company based in Sydney, Australia. The company’s primary focus is on the cancer immunotherapy by...
    Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

    Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study:...

    Imugene Limited (ASX: IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range...

    Imugene released Presentation on KEY-Vaxx and B-Vaxx Cancer Vaccine Programs for the 2019 AACR

    Imugene Limited (ASX: IMU) is a biotechnology company with operations in America and Europe. The company is into the development of biologic therapies for...

    Imugene’s Shares zoomed up by 17.65% on the declaration of Half-year results

    Imugene Limited (ASX: IMU) has released its half-year results ended 31 December 2018. As at 31 December 2018, the group recorded a loss for...

    Imugene Reported Cancer Research Publishing In The Prestigious American Journal

    Imugene Limited (ASX: IMU), which is in the business of clinical stage immuno-oncology, IS building up a range of new and novel immunotherapies that...
    Imugene Releases Bioshares

    Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer...

    Imugene Limited (ASX: IMU), the immuno-oncology company, with its unique technological platform basically tries to harness the immune system of the cancer patients and...

    Recent News